sanofi's malaria gameplan

sanofi-aventis Group does not expect to make any money from developing drugs to treat tropical diseases in either the developed or the developing world. Rather, the mandate of the company's Access to Medicines unit is to develop malaria and tuberculosis drugs without losing money.

Last month, sanofi announced a memorandum of understanding to work with Medicines for Malaria Venture (MMV) in hopes of adding compounds to the pharma's malaria pipeline and offsetting the cost of drug development...